As GSK's vaccine ambitions grow with the launch of new respiratory syncytial virus (RSV) shot Arexvy, the company is once again investing to support its manufacturing operations. The British pharma is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback